Phase III Study to Evaluate the Efficacy and Safety of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome

Exclusion Criteria

• •Patient with history of surgical resection of stomach, gallbladder, small intestine, or large intestine (excluding resection of appendicitis and benign polyp)
• •Patient with history or current affection of inflammatory bowel disease (Crohn's disease or ulcerative colitis)
• •Patient with history or current affection of ischemic colitis
• •Patient currently affected by infectious enteritis
• •Patient currently affected by hyperthyroidism or hypothyroidism
• •Patient currently affected by active peptic ulcer
• •In the case of a female patient, the one currently affected by endometriosis or uterine adenomyosis
• •Patient with high depression or anxiety considered to influence drug evaluation
• •Patient with history of abuse of drug or alcohol within a year before consent acquisition, or with current abuse
• •Patient who used or underwent or will use or undergo drug/therapy/test prohibited to combine 3 days before the start of bowel habit observation period (Day -17) or thereafter
• •Patient with history or current affection of malignant tumor
• •Patient currently affected by serious cardiovascular disease, respiratory disease, kidney disease, hepatic disease, gastrointestinal disease (excluding IBS), hemorrhagic disease, or neural/mental disease
• •Patient with history of drug allergy